CHUM-Hotel-Dieu de Montreal

Montreal, Quebec H2W 1T8

0 studies enrolling now · 9 studies all time

What they study most

Atrial Fibrillation, Atrial Flutter, Breast Adenocarcinoma, Breast Cancer, Breast Ductal Carcinoma In Situ, Estrogen Receptor Negative, HER2/Neu Negative, HER2/Neu Positive, Hormone Receptor Positive, Invasive Breast Carcinoma, Malignant Salivary Gland Neoplasm, Multicentric Breast Carcinoma

Studies at this site

• Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer — Running, not enrolling
• Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) — Running, not enrolling
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer — Running, not enrolling
• Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer — Completed
• Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy — Completed
• Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer — Completed
• Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors — Completed
• A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter — Completed
• Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation — Completed